News | August 09, 2011

Boston Scientific Announces Favorable Court Ruling Dismissing Securities Fraud Case

August 9, 2011 — Boston Scientific Corp. said the U.S. Court of Appeals for the First Circuit has affirmed the dismissal of a securities fraud case in connection with the 2004 recall of one of the company’s coronary stent systems.

The U.S. District Court for the District of Massachusetts had previously dismissed the case, which had been filed by the Mississippi Public Employees’ Retirement System.

"We are pleased with the court's decision," said Tim Pratt, executive vice president, chief administrative officer and general counsel for Boston Scientific. "The company has made significant progress in reducing its legal exposure in the last 24 months and will continue to vigorously defend itself against allegations of this type."

The Mississippi Public Employees' Retirement System is a pension fund and purchaser of Boston Scientific stock. The system alleged company executives both withheld material information about problems with the Taxus Express2 paclitaxel-eluting coronary stent and decisions addressing those problems. It also alleged the company made misleading positive statements, in violation of sections 10(b) and 20(a) of the Securities Exchange Act of 1934, 15 78j(b) and 78t(a), and the attendant rules and regulations.

The plaintiff alleged these false and misleading statements caused the market price of the company's securities to be artificially inflated, harming investors.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  

For more information: www.bostonscientific.com

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Overlay Init